市場調查報告書
商品編碼
391485

急性淋巴性白血病治療藥的全球市場:成長,趨勢,及預測

Acute Lymphoblastic Leukemia Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球急性淋巴性白血病治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,細胞類別·治療類別·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各細胞類別
  • 各治療類別
    • 化療
    • 標靶治療
    • 放射線治療
    • 幹細胞移植
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 產業內的競爭

  • 企業簡介
    • Bristol Myer Squibb Company
    • Celegene Corporation
    • Eisai
    • Erytech Pharma
    • F. Hoffmann-La Roche Ltd
    • Genmab A/S
    • GlaxoSmithKline
    • Novartis AG
    • Pfizer Inc
    • Sanofi SA
    • SymBio Pharmaceuticals Limited

第7章 市場機會及未來趨勢

目錄
Product Code: 46740

One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.

There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.

Key Market Trends

Chemotherapy is Expected to Dominate the Type of Therapy Segment

The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.

Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.

North America to Dominate the Market Over the Forecast Period

North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.

Competitive Landscape

The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
    • 4.2.2 Increasing Initiatives Taken by the Government and Private Organizations
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Pathways
    • 4.3.2 High Cost Asscoiated with the Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Cell
    • 5.1.1 B-cell ALL
    • 5.1.2 T-cell ALL
    • 5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
  • 5.2 By Type of Therapy
    • 5.2.1 Chemotherapy
      • 5.2.1.1 Hyper - CVAD Regimen
      • 5.2.1.2 CALGB 8811 Regimen
      • 5.2.1.3 Linker Regimen
      • 5.2.1.4 Nucleoside Inhibitors
      • 5.2.1.5 Other Types of Therapies
    • 5.2.2 Targeted Therapy
    • 5.2.3 Radiation Therapy
    • 5.2.4 Stem Cell Transplantation
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bristol Myer Squibb Company
    • 6.1.2 Celegene Corporation
    • 6.1.3 Eisai Co Ltd
    • 6.1.4 Erytech Pharma
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Genmab A/S
    • 6.1.7 GlaxoSmithKline PLC
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS